Sodium-Endothelial Function-CKD Study

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. Abnormalities of a metabolic pathway called the "L-arginine-nitric oxide" pathway are thought to be particularly important in these people, and previous research in animals has suggested that sodium (salt) affects part of this metabolic pathway. The purpose of our research is to study the effects of sodium intake on the "L-arginine-nitric oxide" pathway, and on blood vessel function, in patients with kidney disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St George's, University of London
• Collaborators: British Heart Foundation; St. George's Hospital Charitable Foundation

Criteria

Inclusion Criteria:

• CKD Stages 2 and 3 [= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula]

• 18 to 75 years old

Exclusion Criteria:

• >3 g/24 hours of proteinuria

• Uncontrolled hypertension (systolic BP >160 mmHg, diastolic BP >100 mmHg on/off anti-hypertensive medication)

• Diabetes mellitus

• Tobacco smoking

• Total fasting cholesterol >6 mmol/L

• Uncontrolled heart failure or active IHD

• Chronic liver failure

• Active malignancy